Abstract
The vagal nerve conveys primary afferent information from the intestinal mucosa to the brain stem. Activation of vagal afferent fibers results in inhibition of food intake, gastric emptying, and stimulation of pancreatic secretion. Afferents nerves terminating near to the mucosa are in a position to monitor the composition of the luminal contents. As afferents do not project directly into the lumen, their activation depends on an intermediary step, i.e. neuronal activation by a secondary substance released from within the mucosal epithelium. This review addresses the role for both cholecytokinin (CCK) and serotonin (5-HT) released from enteroendocrine cells and acting as paracrine agents on the terminals of vagal afferents in responses to a number of luminal signals. CCK acted on both high- and lowaffinity CCK-A receptors present on distinct vagal primary afferent neurons. Neurons of the nodose ganglia respond to intraduodenal perfusions of maltose, glucose, and hypertonic saline. These neurons were also sensitive to exogenous luminally applied 5-HT at concentrations that mimic physiologic levels. Intravenous administration of a 5-HT3 antagonist blocked these responses suggesting that nodose neuronal responses to luminal osmolarity and to the digestion products of carbohydrates are dependent on the release of endogenous 5- HT from the mucosal enterochromaffin (EC) cells, which acts on the 5-HT3 receptors on vagal afferent fibers to stimulate vagal afferent neurons. Double-labeling studies revealed that nodose neurons responded to 5-HT-dependent luminal stimuli contain mainly glutamate and substance P. Over the past year or so it has become clear that there are multiple possible excitatory inputs to a common vagal afferent route with synergistic interactions being common. The nodose ganglion contains neurons that may possess only high- or low-affinity CCK-A receptors or 5-HT3 receptors. Some neurons that express high-affinity CCK-A receptors also express 5-HT3 receptors and (or) secretin receptors. Pre-exposure to luminal 5-HT may augment the subsequent response to a subthreshold dose of CCK. Synergistic interaction between CCK and secretin also occurs at the nodose ganglia; this is mediated by high affinity CCK-A receptor. This may explain the robust postprandial secretion of enzyme, bicarbonate, and fluid despite the modest increase in CCK after a meal. Some neurons that possess low-affinity CCK-A receptor colocalize with leptin receptors (OB-Rs). These neurons also respond to mechanical distention. Interaction between CCK-A receptor and OB-Rs in these neurons likely facilitates leptin mediation of short-term satiety.
Keywords: Sensory transduction, Vagus nerve, Nodose ganglia, Cholecytokinin, Serotonin, Macronutrients, Endocrine and Enterochromaffin cells, Synergistic interactions
Current Medicinal Chemistry
Title: Sensory Signal Transduction in the Vagal Primary Afferent Neurons
Volume: 14 Issue: 24
Author(s): Ying Li and Ying Li
Affiliation:
Keywords: Sensory transduction, Vagus nerve, Nodose ganglia, Cholecytokinin, Serotonin, Macronutrients, Endocrine and Enterochromaffin cells, Synergistic interactions
Abstract: The vagal nerve conveys primary afferent information from the intestinal mucosa to the brain stem. Activation of vagal afferent fibers results in inhibition of food intake, gastric emptying, and stimulation of pancreatic secretion. Afferents nerves terminating near to the mucosa are in a position to monitor the composition of the luminal contents. As afferents do not project directly into the lumen, their activation depends on an intermediary step, i.e. neuronal activation by a secondary substance released from within the mucosal epithelium. This review addresses the role for both cholecytokinin (CCK) and serotonin (5-HT) released from enteroendocrine cells and acting as paracrine agents on the terminals of vagal afferents in responses to a number of luminal signals. CCK acted on both high- and lowaffinity CCK-A receptors present on distinct vagal primary afferent neurons. Neurons of the nodose ganglia respond to intraduodenal perfusions of maltose, glucose, and hypertonic saline. These neurons were also sensitive to exogenous luminally applied 5-HT at concentrations that mimic physiologic levels. Intravenous administration of a 5-HT3 antagonist blocked these responses suggesting that nodose neuronal responses to luminal osmolarity and to the digestion products of carbohydrates are dependent on the release of endogenous 5- HT from the mucosal enterochromaffin (EC) cells, which acts on the 5-HT3 receptors on vagal afferent fibers to stimulate vagal afferent neurons. Double-labeling studies revealed that nodose neurons responded to 5-HT-dependent luminal stimuli contain mainly glutamate and substance P. Over the past year or so it has become clear that there are multiple possible excitatory inputs to a common vagal afferent route with synergistic interactions being common. The nodose ganglion contains neurons that may possess only high- or low-affinity CCK-A receptors or 5-HT3 receptors. Some neurons that express high-affinity CCK-A receptors also express 5-HT3 receptors and (or) secretin receptors. Pre-exposure to luminal 5-HT may augment the subsequent response to a subthreshold dose of CCK. Synergistic interaction between CCK and secretin also occurs at the nodose ganglia; this is mediated by high affinity CCK-A receptor. This may explain the robust postprandial secretion of enzyme, bicarbonate, and fluid despite the modest increase in CCK after a meal. Some neurons that possess low-affinity CCK-A receptor colocalize with leptin receptors (OB-Rs). These neurons also respond to mechanical distention. Interaction between CCK-A receptor and OB-Rs in these neurons likely facilitates leptin mediation of short-term satiety.
Export Options
About this article
Cite this article as:
Li Ying and Li Ying, Sensory Signal Transduction in the Vagal Primary Afferent Neurons, Current Medicinal Chemistry 2007; 14 (24) . https://dx.doi.org/10.2174/092986707782023334
DOI https://dx.doi.org/10.2174/092986707782023334 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Intracompartmental Delivery of CNTF as Therapy for Huntingtons Disease and Retinitis Pigmentosa
Current Gene Therapy Cardiovascular Effects of Methotrexate in Rheumatoid Arthritis Revisited
Current Medicinal Chemistry Onconeural Versus Paraneoplastic Antigens?
Current Medicinal Chemistry Neurochemistry Changes Associated with Mutations in Familial Parkinsons Disease
Current Medicinal Chemistry Evolving Therapeutic Targets in Ischemic Stroke: A Concise Review
Current Drug Targets HIV-1-Associated Dementia During HAART Therapy
Recent Patents on CNS Drug Discovery (Discontinued) Genes Involved in Hereditary Hearing Impairment
Current Genomics Positron Emission Tomography and Brain Monoamine Neurotransmission - Entries for Study of Drug Interactions
Current Pharmaceutical Design Metal and Inflammatory Targets for Alzheimers Disease
Current Drug Targets Anti-Inflammatory Role of Fetuin-A in Injury and Infection
Current Molecular Medicine Mitochondrial Encephalomyopathies in Children. Part II: Advanced MR Tools and the Importance for its Early Recognition in the Acute Clinical Setting
Current Medical Imaging GABA Puts a Stop to Pain
Current Drug Targets - CNS & Neurological Disorders Post-stroke Depression Therapy: Where are we now?
Current Neurovascular Research Nanomedicine against Alzheimer’s and Parkinson’s Disease
Current Pharmaceutical Design Molecular Pathophysiology of Renal Tubular Acidosis
Current Genomics Central Nervous System Abnormalities in Fibromyalgia and Chronic Fatigue Syndrome: New Concepts in Treatment
Current Pharmaceutical Design Older Adults with Amnestic Mild Cognitive Impairment Exhibit Exacerbated Gait Slowing under Dual-Task Challenges
Current Alzheimer Research Adolescent HIV-1 Transgenic Rats: Evidence for Dopaminergic Alterations in Behavior and Neurochemistry Revealed by Methamphetamine Challenge
Current HIV Research Magnetic Resonance Imaging of Iron in Parkinsons Disease
Current Medical Imaging HIV-1 Proteins, Tat and gp120, Target the Developing Dopamine System
Current HIV Research